Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 3

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Neoplasms 6Prostatic Neoplasms 3Lymphoma, Follicular 3Leukemia, Lymphocytic, Chronic, B-Cell 3Small Cell Lung Carcinoma 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Waldenstrom Macroglobulinemia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Laryngeal Neoplasms 1Hormone Refractory Prostate Cancer 1Gliosarcoma 1Glioblastoma 1Extensive Stage Small Cell Lung Cancer 1Disease 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Brain Neoplasms 1Adrenocortical Carcinoma 1

Interventions

Docetaxel 158Prednisone 131Leuprolide 95bicalutamide 86enzalutamide 83Radiotherapy 80Goserelin 80Abiraterone Acetate 76acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 54Magnetic Resonance Spectroscopy 46Zoledronic Acid 44gallium 68 PSMA-11 37Flutamide 34abiraterone 32Estramustine 32radium Ra 223 dichloride 30apalutamide 27Surveys and Questionnaires 26Gonadotropin-Releasing Hormone 26Androgen Antagonists 25cabazitaxel 24Radiosurgery 24Dutasteride 22sipuleucel-T 21Prednisolone 21Triptorelin Pamoate 20Paclitaxel 20luprolide acetate gel depot 19Radiation 19Exercise 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Prostatic Neoplasms × gossypol acetic acid × Clear all
NCT00666666 2014-12-18

R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
55 enrolled 13 charts
Genitourinary

Prostatic Neoplasms

NCT00286793 2011-06-29

Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC

Ascenta Therapeutics

Phase 1/2 Completed
76 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT00571675 2010-11-09

A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)

Ascenta Therapeutics

Phase 2 Completed
220 enrolled
Genitourinary

Disease, Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡